Journal of Histochemistry and Cytochemistry Priciples for Free Access to Science
  Search:   
    >> Advanced Search

Guidelines | Subscriptions | About | exPRESS - Current - Archive | Business Information | Contact
DOI: 10.1369/jhc.4A6279.2004
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Samuelsson, S.
Right arrow Articles by Isfort, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Samuelsson, S.
Right arrow Articles by Isfort, R. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Histochemistry and Cytochemistry
Volume 52 (7): 967-977, 2004
Copyright ©The Histochemical Society, Inc.

Corticotropin-releasing Factor 2 Receptor Localization in Skeletal Muscle

Steven Samuelsson1, Jana S. Lange, Richard T. Hinkle, Mark Tarnopolsky and Robert J. Isfort

Research Division, Procter & Gamble Pharmaceuticals, Mason, Ohio (SS,JSL,RTH,RJI), and Department of Pediatrics and Medicine, McMaster University, Hamilton, Ontario, Canada (MT)

Correspondence to: Dr. Robert J. Isfort, Research Division, Procter & Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason–Montgomery Road, Mason, OH 45040-9317. E-mail: isfort.rj{at}pg.com


   Summary
Top
 Summary
Introduction
 Materials and Methods
 Results
 Discussion
 Literature Cited
 
Our objective in this study was to localize the corticotropin-releasing factor 2 receptor (CRF2R) in rodent and human skeletal muscle. We found CRF2R protein to be abundant in neural tissues in skeletal muscle, including large nerve fibers and bundles, neural tissue associated with mechanoreceptors, muscle spindles, and the Golgi tendon organ. CRF2R protein was also abundant in blood vessels in skeletal muscle. CRF2R protein was also observed, although with less abundance, in the endo/perimysial regions in skeletal muscle. The localization of the CRF2R to blood vessels is consistent with the CRF2R-mediated vascular phenomena observed previously, but the observation of CRF2R in neural tissue in skeletal muscle is a novel finding with an unknown function.

(J Histochem Cytochem 52:967–977, 2004)

Key Words: corticotropin-releasing factor • receptor • skeletal muscle • neural tissues


   Introduction
Top
 Summary
 Introduction
Materials and Methods
 Results
 Discussion
 Literature Cited
 
TWO CORTICOTROPIN-RELEASING FACTOR RECEPTORS have been identified, the corticotropin-releasing factor 1 receptor (CRF1R) and the corticotropin-releasing factor 2 receptor (CRF2R), both of which belong to G protein coupled, seven transmembrane receptor family (Dautzenberg and Hauger 2002Go). Many CRFRs have been cloned, including the rodent and human CRF1R and CRF2R, with unique distribution patterns observed for each receptor (De Souza 1995Go; Chalmers et al. 1996Go; Dieterich et al. 1997Go). Gene ablation of both the CRF1R and CRF2R has recently been reported, with CRF1R knockout mice demonstrating impaired stress response and reduced anxiety behavior, while CRF2R knockout mice demonstrated an impaired food intake reduction after stimulation with urocortin I, lack of vasodilatation after stimulation with urocortin I, a normal stress response, and postnatal hypervasculatization (Smith et al. 1998Go; Timpl et al. 1998Go; Bale et al. 2000Go,2002Go; Coste et al. 2000Go; Kishimoto et al. 2000Go). It is hypothesized that the CRF2R moderates the effects of activation of the CRF1R and the HPA axis stress response. The CRFRs can be distinguished pharmacologically through the use of receptor-elective agonists and antagonists (Chalmers et al. 1996Go; McCarthy et al. 1999Go; Radulovic et al. 1999Go; Hsu and Hsueh 2001Go; Lewis et al. 2001Go; Reyes et al. 2001Go; Martinez et al. 2002Go). These selective agonists and antagonists, along with the CRFR knockout mice, have been useful in determining which CRF receptor mediates specific biological responses. Of the two CRFRs, only CRF2R RNA is expressed in skeletal muscle (Kishimoto et al. 1995Go; Lovenberg et al. 1995Go; Heldwein et al. 1997Go).

Recently we have discovered that activation of the CRF2R modulates skeletal muscle mass under physiological and pathological conditions (Hinkle et al. 2003Go). We have also demonstrated that the CRF2R protein expressed in skeletal muscle is active and positively coupled to G{alpha}s (Hinkle et al. 2003Go). Therefore, the CRF2Rs expressed in skeletal muscle are biologically active and appear to have a role in the maintenance of skeletal muscle mass. Although CRF2R protein localization has been demonstrated in several tissues, the location of the CRF2R in skeletal muscle has not been investigated. We have undertaken experiments designed to localize CRF2R expression in skeletal muscle.


   Materials and Methods
Top
 Summary
 Introduction
 Materials and Methods
Results
 Discussion
 Literature Cited
 
Six-week-old male and female Sprague–Dawley rats (Charles River; Raleigh, NC) and C57Bl6 mice (Charles River) were housed singly and acclimatized to the conditions of the facility for ~1 week before use. Mice and rats had access to lab chow and water ad libitum. Animals were subjected to standard conditions of humidity, temperature, and a 12-hr light cycle. All studies described in this report were conducted in compliance with the US Animal Welfare Act and rules and regulations of the State of Ohio Departments of Health, and were approved by the local IUCAC. Rat and mouse lower leg muscles (tibialis anterior and medial gastrocnemius muscles) were obtained by removing the indicated muscles and immediately placing the muscles in optimal cutting temperature (OCT) compound (Sakura Finetek; Torrance, CA). Tissues in OCT compound were frozen in liquid nitrogen-cooled isopentane and held at –70C. Human vastus lateralis muscle biopsies from healthy young adults, frozen in OCT, were obtained from Dr. Mark Tarnopolsky (McMaster University; Hamilton, Ontario, Canada). Human muscle biopsies were obtained under the approval from the McMaster University Ethics Committee. Two anti-CRF2R antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA) and were used throughout this study. The CRFR (C-20, sc-1757) antibody reacts with both CRFR1 and CRFR2, while the CRFR2 (N-20, sc-1826) antibody is specific for CRFR2. Anti-CRFR1 and -CRFR2 (RDI-CRFR1CabG, RDI-RTCRFR2NabG) antibodies (Research Diagnostics; Flanders, NJ) were used to validate results obtained with the Santa Cruz products. The specificity of each CRFR antibody was established by running preadsorption controls. Each antibody was preincubated for 4 hr with a 5000-fold molar excess of its corresponding peptide (sc-1757P for C20 and sc-1826P for N20) or an irrelevant peptide. The antigen–antibody mixture was centrifuged at 100,000 x g for 30 min with the supernatant used in place of primary antibody in the normal immunocytochemistry protocol. Preadsorbed samples were processed in parallel with normal CRFR antiserum to optimize comparative staining.

Immunocytochemical analysis was performed on 7-µm frozen sections by indirect labeling, as follows. Cryostat sections were attached, the slides were warmed to room temperature, sections were encircled with a PAP pen, and were hydrated in PBS. Sections were permeabilized in PBS/0.1% Triton X-100 for 30 min, aspirated, and covered with blocking buffer of 10% normal donkey serum (NDS) in BSA buffer [2% bovine serum albumin (BSA)/0.1 M phosphate buffer, pH 7.4] for 1 hr at room temperature (RT). Primary antibodies were diluted in BSA buffer, and sections were incubated directly, after aspiration of blocking solution, for 1 hr at RT. Slides were washed three times for 10 min in PBS, then incubated with fluorescein-conjugated donkey secondary antibodies (Jackson Immunoresearch Labs; West Grove, PA) at 5 µg/ml in BSA buffer with 0.5 µM diamidinophenylindole dihydrochloride (DAPI; Molecular Probes, Eugene, OR) for 1 hr at RT. Sections were washed twice for 10 min in PBS with a final wash in 0.1 M Tris buffer, pH 8.5. Sections were coverslipped under PPD glycerol (10% 1 M Tris, 90% glycerol, pH 8.5, containing 1 mg/ml p-phenylenediamine), sealed with nailpolish, and stored at –20C. Tissue sections were examined with a Nikon Microphot FXA (Melville, NY). Images were captured with a Spot II digital camera (Diagnostic Instruments; Sterling Heights, MI) and processed using Metamorph 4.6 imaging software (Universal Imaging; Downingtown, PA).

Co-localization analyses were performed with the following landmark antibodies and filter sets appropriate for fluorescein and Cy-3: {alpha}-smooth muscle actin (A2547; Sigma Chemical, St Louis, MO); ß-tubulin (T4026; Sigma Chemical; neurofilament (34-1000; Zymed Laboratories, San Francisco, CA); PGP9.5 (UC RA 95101; Accurate Chemical and Scientific, Westbury, NY); nestin (rat-401; Developmental Studies Hybridoma Bank, Iowa City, IA); and rhodamine-labeled {alpha}-bungarotoxin (B13421; Molecular Probes).


   Results
Top
 Summary
 Introduction
 Materials and Methods
 Results
Discussion
 Literature Cited
 
CRF2R localization in rat, mouse and human skeletal muscle was performed using two antibodies, one that was CRFR-specific with equivalent affinity for both CRF1R and CRF2R (C20) and a second that was specific for CRF2R only. Staining was considered positive if both antibodies stained the same structures. Both of these antibodies were crossreactive with mouse, rat, and human CRF2R, allowing cross-species comparison. In addition, we attempted to localize the CRF2R to specific substructures in skeletal muscle using antibodies specific for proteins found in neurons (neurofilament and PGP9.5) (Krikler et al. 1992Go; Nahirney and Ovalle 1993Go; Blumer et al. 2001Go; Kawabuchi et al. 2001Go), proteins found on blood vessel ({alpha}-smooth muscle actin) (Nora et al. 1998Go), and proteins found at the myotendinous junction (tubulin and nestin) (Ralphs et al. 1991Go; Yarnitzky et al. 1997Go; Carlsson et al. 1999Go; Vaittinen et al. 1999Go). In addition, we used rhodamine-conjugated {alpha}-bungarotoxin (Molecular Probes) to co-localize CRF2R staining to the neuromuscular junction. With these tools, we observed CRF2R protein staining in large nerve bundles and intrafusal fibers of muscle, where it co-localized with neuronal markers PGP9.5 and neurofilament protein staining (Figures 1, 2, and 3) . At neuromuscular junctions, CRF2R staining co-localized with bungarotoxin (Figure 4) . Rhodamine-conjugated {alpha}-bungarotoxin was used to delineate the postsynaptic membrane of the neuromuscular junction, where it binds tightly to the acetylcholine receptors (Blumer et al. 2001Go; Kawabuchi et al. 2001Go).



View larger version (74K):
[in this window]
[in a new window]
  		Figure 1

Immunofluorescence micrographs showing the co-localization of CRFR antibodies C-20 (CRFR-specific) and N-20 (CRF2R-specific) with the neural marker PGP9.5 in large neural structures of rat skeletal muscle. Magnification x20.

 


View larger version (44K):
[in this window]
[in a new window]
  		Figure 2

Immunofluorescence micrographs showing the co-localization of CRFR antibodies C-20 and N-20 with the neural marker neurofilament in large neural structures of rat skeletal muscle. Magnification x20.

 


View larger version (57K):
[in this window]
[in a new window]
  		Figure 3

Immunofluorescence micrographs showing the co-localization of the CRFR antibody C-20 with the neuronal marker neurofilament in a large neural structure of mouse skeletal muscle. Magnification x40.

 


View larger version (60K):
[in this window]
[in a new window]
  		Figure 4

Longitudinal sections of rat diaphragm muscle showing co-localization of CRFR antibodies C-20 and N-20 with {alpha}-bungarotoxin (BTX). Magnification x20.

 
CRF2R protein staining was also observed at the myotendinous junction, where it is co-expressed with nestin and tubulin (Figure 5) . CRF2R protein staining was enriched on blood vessels; CRF2R staining co-localized with smooth muscle actin staining (Figure 6) . Finally, CRF2R staining was found in the endo- and perimysium surrounding rat, mouse, and human muscle fibers (Figure 7) . These connective tissue regions contain small arterioles, capillaries, venules, fibroblasts, neural processes, and satellite cells. CRF2R staining in all the human skeletal muscle samples was similar (five males and five females). Because of sampling limitations for human skeletal muscle, we were unable to evaluate CRF2R staining at myotendinous junction, neuronal, and vascular regions (samples were needle biopsies taken from the belly of the vastus lateralis muscle). Finally, C20 and N20 antibody specificity was evaluated by blocking antibody binding with peptide immunogen compared with staining in which the antibody was blocked with an irrelevant peptide. The blocking data were used in conjunction with our control data to establish staining and antibody specificity (Figure 8) .



View larger version (88K):
[in this window]
[in a new window]
  		Figure 5

Longitudinal sections through the transition region between rat skeletal muscle fibers and their associated tendon (myotendinous junction), showing co-localization of CRFR antibody C-20 with nestin and tubulin. Magnification x20.

 


View larger version (66K):
[in this window]
[in a new window]
  		Figure 6

Immunofluorescence micrographs showing the co-localization of CRFR antibodies C-20 and N-20 with smooth muscle actin (S.M. Actin) in blood vessels of rat skeletal muscle. Magnification x20.

 


View larger version (83K):
[in this window]
[in a new window]
  		Figure 7

Immunofluorescence micrographs of cross- and longitudinal sections through human (S21 and S2), mouse and rat skeletal muscle demonstrating localization of the CRFR antibodies with C-20 and N-20. Magnification x20.

 


View larger version (35K):
[in this window]
[in a new window]
  		Figure 8

CRFR antibodies C-20 and N-20 staining specificity in mouse skeletal muscle. Immunoreactivity was blocked with the peptide immunogen but was not blocked with an irrelevant peptide. Magnification x20.

 

   Discussion
Top
 Summary
 Introduction
 Materials and Methods
 Results
 Discussion
Literature Cited
 
In this study we showed that the CRF2R in skeletal muscle localized to neural structures, blood vessels, myotendinous junctions, and endomysial/perimysial spaces. Interestingly, expression of the CRF2R in skeletal muscle myocytes was not observed. This raises the possibility that the effects of CRF2R activation on skeletal muscle mass may be an indirect effect, potentially secondary to activation of the CRF2R on either nerves, blood vessels, myotendinous junction, or endo/perimysium. Current understanding of CRF2R effects on skeletal muscle does not provide conclusive evidence about which of these sites of CRF2R expression is critical for the skeletal muscle mass effects of CRF2R activation. However, it can be inferred from the data presented here that the effects of CRF2R activation on skeletal muscle mass are an indirect myocyte effect. One possibility that is consistent with known CRFR biology in other tissues is that activation of the CRF2R results in the release of trophic factors from nerve endings, factors that directly increase skeletal muscle mass. In particular, it is known that members of the CRH family of ligands function as neurohumoral factors (Garzon et al. 1985Go; McAlexander and Undem 1997Go; Heymann-Monnikes et al. 1991Go; Tamaoki et al. 1998Go; McCarthy et al. 1999Go; Grill et al. 2000Go; Wang et al. 2000Go; Kihara et al. 2001Go; Dautzenberg and Hauger 2002Go; Miampamba et al. 2002Go). It has been observed that peripheral CRFR agonistic peptides activate CRFR on neurons in the colon, bronchi, stomach, airway smooth muscle, ileum, and duodenum (Garzon et al. 1985Go; Heymann-Monnikes et al. 1991Go; McAlexander and Undem 1997Go; Tamaoki et al. 1998Go; McCarthy et al. 1999Go; Grill et al. 2000Go; Wang et al. 2000Go; Kihara et al. 2001Go; Dautzenberg and Hauger 2002Go; Miampamba et al. 2002Go). The effect of CRFR activation in these tissues is directly mediated either by stimulation of the CRFR on the nerves that innervate that tissue or by potentiating the action of other neurohumoral factors. In addition, it is known that neural release of trophic factors is an important mechanism for the maintenance of skeletal muscle mass. Therefore, the indirect release of these factors via CRF2R activation is a viable mechanism of CRF2R action for mediating myocyte mass (Bray and Harris 1975Go; Markelonis et al. 1980Go; Davis 1983Go; Helgren et al. 1994Go; Fernandez et al. 1999Go; Marques and Neto 1997Go. Alternatively, activation of the CRF2R expressed at the myotendinous junction may provide a feedback loop connected with muscle use, resulting in increased muscle mass through a neuronally mediated mechanism, possibly through the release of trophic factors. Localization of the CRF2R at the myotendinous junction and co-localizing with nestin indicates that the CRF2R may be part of the Golgi tendon organ, a nerve rich portion of the tendon involved in mechanosensation (Swett and Schoultz 1975Go). In addition, CRF2R associated with free nerve endings found throughout skeletal muscle and with muscle spindles may also regulate the release of trophic factors associated with increased muscle use because both of these neural structures are involved in mechanosensation (Stacey 1969Go; Mense and Meyer 1985Go; Hunt 1990Go; Nahirney and Ovalle 1993Go).

Do CRF2Rs present on blood vessels or in the endo/perimysium function to modulate skeletal muscle mass? CRF2Rs present on blood vessels are known to have an important role in the control of blood pressure and vasodilatation (Coste et al. 2000Go). It is unclear how vasodilatation would function to regulate skeletal muscle mass other than to release fluid content in muscle. We have previously demonstrated that the increase in muscle mass observed after CRF2R activation is mediated by increased myocyte mass and by myocyte cross-sectional and myocyte force production (Hinkle et al. 2003Go). Therefore, CRF2R activation does more than increase fluid content in muscle. It is possible that vasodilatation leads to increased exposure of myocytes to serum anabolic growth factors, such as IGF-1, a known skeletal muscle anabolic hormone. CRF2R present in the endo/perimysium may have a role in regulating myocyte mass and contractile apparatus protein levels by the production, by fibroblasts or other connective tissue cells present in the endo/perimysium, of anabolic growth factors. This hypothesis does have some support from previously reported experimental evidence demonstrating that activation of CRFR in fibroblast modulates prostaglandin synthesis (Fleisher-Berkovich and Danon 1995Go). The results we report here are not sufficient to validate any of these possible mechanisms. However, the data we present are important because they provide a set of observations that provide insights necessary for the design of future experiments to evaluate the validity of these potential mechanisms of CRF2R action.

In conclusion, CRF2R protein has been localized to neural structures, myotendinous junction, blood vessels, and endo/perimysial space in skeletal muscle. CRF2R expression was not observed on myocytes, even though treatment of skeletal muscle in vivo resulted in increased myocyte mass. The mechanism underlying the effects of CRF2R activation on regulating skeletal muscle mass is presently unknown.


   Footnotes
 
1 Present address: Eyetech Pharmaceuticals Inc., Eyetech Research Center, Woburn, MA. Back

Received for publication February 10, 2004; accepted February 24, 2004


   Literature Cited
Top
 Summary
 Introduction
 Materials and Methods
 Results
 Discussion
 Literature Cited
 

Bale TL, Contarino A, Smith GW, Chan R, Gold LH, Sawchenko PE, Koob GF, et al. (2000) Mice deficient for corticotropin-releasing hormone receptor 2 display anxiety-like behavior and are hypersensitive to stress. Nature Genetics 24:410–414[CrossRef][Medline]

Bale TL, Giordano FJ, Hickey RP, Huang Y, Nath AK, Peterson KL, Vale WW, et al. (2002) Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization. Proc Natl Acad Sci USA 99:7734–7739[Abstract/Free Full Text]

Blumer R, Wasicky R, Hotzenecker W, Lukas JR (2001) Presence and structure of innervated myotendinous cylinders in rabbit extraocular muscle. Exp Eye Res 73:787–796[CrossRef][Medline]

Bray JJ, Harris AJ (1975) Dissociation between nerve-muscle transmission and nerve trophic effects on rat diaphragm using type D botulinum toxin. J Physiol 253:53–77[Abstract/Free Full Text]

Carlsson L, Li Z, Paulin D, Thornell LE (1999) Nestin is expressed during development and in myotendinous and neuromuscular junctions in wild type and desmin knockout mice. Exp Cell Res 251:213–223[CrossRef][Medline]

Chalmers DT, Lovenberg TW, Gridoriadis DE, Behan DP, De Souza EB (1996) Corticotropin-releasing factor receptors: from molecular biology to drug design. Trends Pharmacol Sci 17:166–172.[CrossRef][Medline]

Coste SC, Kesterson RA, Heldwein KA, Stevens SL, Heard AD, Hollis JH, Murray SE, et al. (2000) Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor 2. Nature Genet 24:403–409[CrossRef][Medline]

Dautzenberg FM, Hauger RL (2002) The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci 23:71–77[CrossRef][Medline]

Davis HL (1983) Trophic action of nerve extract on denervated skeletal muscle in vivo: dose dependency, species specificity, and timing of treatment. Exp Neurol 80:383–394[CrossRef][Medline]

De Souza EB (1995) Corticotropin-releasing factor receptors: physiology, pharmacology, biochemistry and role in central nervous system and immune disorders. Psychoneuroendocrinology 20:789–819[CrossRef][Medline]

Dieterich KD, Lehnert H, De Souza EB (1997) Corticotropin-releasing factor receptors: an overview. Exp Clin Endocrinol Diabetes 10:65–82

Fernandez HL, Ross GS, Nadelhaft I (1999) Neurogenic calcitonin gene-related peptide: a neurotrophic factor in the maintenance of acetylcholinesterase molecular forms in adult skeletal muscle. Brain Res 844:83–97[CrossRef][Medline]

Fleisher-Berkovich S, Danon A (1995) Effect of corticotropin-releasing factor on prostaglandin synthesis in endothelial cells and fibroblasts. Endocrinology 136:4068–4072[Abstract]

Garzon J, Hollt V, Schulz R, Herz A (1985) Excitatory neuropeptides activate opioid mechanisms in the guinea pig ileum. Neuropeptides 5:583–586[CrossRef][Medline]

Grill HJ, Markison S, Ginsberg A, Kaplan JM (2000) Long-term effects on feeding and body weight after stimulation of forebrain or hindbrain CRH receptors with urocortin. Brain Res 867:19–28[CrossRef][Medline]

Heldwein KA, Duncan JE, Stenzel P, Rittenberg MB, Stenzel-Poore MP (1997) Endotoxin regulates corticotropin-releasing hormone receptor 2 in heart and skeletal muscle. Mol Cell Endocrinol 131:167–172[CrossRef][Medline]

Helgren ME, Squinto SP, Davis HL, Parry DJ, Boulton TG, Heck CS, Zhu Y, et al. (1994) Trophic effect of ciliary neurotrophic factor on denervated skeletal muscle. Cell 76:493–504[CrossRef][Medline]

Heymann-Monnikes I, Tache Y, Trauner M, Weiner H, Garrick T (1991) CRF microinjected into the dorsal vagal complex inhibits TRH analog- and kainic acid-stimulated gastric contractility in rats. Brain Res 554:139–144[CrossRef][Medline]

Hinkle RT, Donnelly E, Cody DB, Samuelsson S, Lange JS, Bauer MB, Tarnopolsky M, et al. (2003) Activation of the CRF2 receptor modulates skeletal muscle mass under physiological and pathological conditions. Am J Physiol 285:E889–898

Hsu SY, Hsueh AJ (2001) Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nature Med 7:605–611[CrossRef][Medline]

Hunt CC (1990) The mammalian muscle spindle: peripheral mechanisms. Physiol Rev 70:643[Abstract/Free Full Text]

Kawabuchi M, Zhou CJ, Wang S, Nakamura K, Liu WT, Hirata K (2001) The spatiotemporal relationship among Schwann cells, axons and postsynaptic acetylcholine receptor regions during muscle reinnervation in aged rats. Anat Rec 264:183–202[CrossRef][Medline]

Kihara N, Fujimura M, Yamamoto I, Itoh E, Inui A, Fujimiya M (2001) Effects of central and peripheral urocortin on fed and fasted gastroduodenal motor activity in conscious rats. Am J Physiol 280:G406–419

Kishimoto T, Pearse RN, Lin CR, Rosenfeld MG (1995) A sauvagine/corticotropin-releasing factor receptor expressed in heart and skeletal muscle. Proc Natl Acad Sci USA 92:1108–1112[Abstract/Free Full Text]

Kishimoto T, Radulovic J, Radulovic M, Lin CR, Schrick C, Hooshmand F, Hermanson O, et al. (2000) Deletion of Crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nature Genet 24:415–419[CrossRef][Medline]

Krikler DM, Rode J, Davies MJ, Woolf N, Moss E (1992) Atrial myxoma: a tumour in search of its origins. Br Heart J 67:89–91[Abstract/Free Full Text]

Lewis K, Li C, Perrin MH, Blount A, Kunitake K, Donaldson C, Vaughan J, et al. (2001) Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA 98:7570–7575[Abstract/Free Full Text]

Lovenberg TW, Chalmers DT, Liu C, De Souza EB (1995) CRF2 alpha and CRF2 beta receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology 136:4139–4142[Abstract]

Markelonis GJ, Kemerer VF, Oh TH (1980) Sciatin: purification and characterization of a myotrophic protein from chicken sciatic nerves. J Biol Chem 255:8967–8970[Abstract/Free Full Text]

Marques MJ, Neto HS (1997) Ciliary neurotrophic factor stimulates in vivo myotube formation in mice. Neurosci Lett 234:43–46[CrossRef][Medline]

Martinez V, Wang L, Rivier JE, Vale W, Tache Y (2002) Differential actions of peripheral corticotropin-releasing factor (CRF), urocortin II, and urocortin III on gastric emptying and colonic transit in mice: role of CRF receptor subtypes 1 and 2. J Pharmacol Exp Ther 301:611–617[Abstract/Free Full Text]

McAlexander MA, Undem BJ (1997) Enhancement of tachykinin-induced contractions of guinea pig .isolated bronchus by corticotropin-releasing factor. Neuropeptides 31:293–299[CrossRef][Medline]

McCarthy JR, Heinrichs SC, Grigoriadis DE (1999) Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications. Curr Pharmacol Des 5:289–315[Medline]

Mense S, Meyer H (1985) Different types of slowly conducting afferent units in the cat skeletal muscle and tendon. J Physiology 363:403–417[Abstract/Free Full Text]

Miampamba M, Maillot C, Million M, Tache Y (2002) Peripheral CRF activates myenteric neurons in the proximal colon through CRF(1) receptor in conscious rats. Am J Physiol 282:G857–865

Nahirney PC, Ovalle WK (1993) Distribution of dystrophin and neurofilament protein in muscle spindles of normal and Mdx dystrophic mice: an immunocytochemical study. Anat Rec 235:501–510[CrossRef][Medline]

Nora EH, Munzenmaier DH, Hansen-Smith FM, Lombard JH, Greene AS (1998) Localization of the ANG II type 2 receptor in the microcirculation of skeletal muscle. Am J Physiol 275:H1395–1403

Radulovic J, Ruhmann A, Liepold T, Spiess J (1999) Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential role of CRF receptors 1 and 2. J Neurosci 19:5016–5025[Abstract/Free Full Text]

Ralphs JR, Benjamin M, Thornett A (1991) Cell and matrix biology of the suprapatella in the rat: a structural and immunocytochemical study of fibrocartilage in a tendon subject to compression. Anat Rec 231:167–177[CrossRef][Medline]

Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, Hogenesch JB, et al. (2001) Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA 98:2843–2848[Abstract/Free Full Text]

Smith GW, Aubry JM, Dellu F, Contarino A, Bilezikjian LM, Gold LH, Chen R, et al. (1998) Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20:1093–1102[CrossRef][Medline]

Stacey MJ (1969) Free nerve endings in skeletal muscle of the cat. J Anat 105:231–254[Medline]

Swett JE, Schoultz TW (1975) Mechanical transduction in the Golgi tendon organ. A hypothesis. Arch Ital Biol 113:374–382[Medline]

Tamaoki J, Sakai N, Kobayashi K, Kanemura T, Shibasaki T, Takizawa T (1998) Corticotropin-releasing factor potentiates the contractile response of rabbit airway smooth muscle to electrical field stimulation but not to acetylcholine. Am Rev Respir Dis 140:1331–1335

Timpl P, Spanagel R, Sillaber I, Kresse A, Reul JM, Stalla GK, Blanquet V, et al. (1998) Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nature Genet 19:162–16[CrossRef][Medline]

Vaittinen S, Lukka R, Sahlgren C, Rantanen J, Hurme T, Lendahl U, Eriksson JE, et al. (1999) Specific and innervation-regulated expression of the intermediate filament protein nestin at neuromuscular and myotendinous junctions in skeletal muscle. Am J Pathol 154:591–600[Abstract/Free Full Text]

Wang L, Martinez V, Vale W, Tache Y (2000) Fos induction in selective hypothalamic neuroendocrine and medullary nuclei by intravenous injection of urocortin and corticotropin-releasing factor in rats. Brain Res 855:47–57[CrossRef][Medline]

Yarnitzky T, Min L, Volk T (1997) The drosophila neuregulin homolog vein mediates inductive interactios between myotubes and their epidermal attachment cells. Genes Dev 11:2691–2700[Abstract/Free Full Text]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 EndocrinologyHome page
S. V. Wu, P.-q. Yuan, L. Wang, Y. L. Peng, C.-Y. Chen, and Y. Tache
Identification and Characterization of Multiple Corticotropin-Releasing Factor Type 2 Receptor Isoforms in the Rat Esophagus
Endocrinology, April 1, 2007; 148(4): 1675 - 1687.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
G. Solinas, S. Summermatter, D. Mainieri, M. Gubler, J. P. Montani, J. Seydoux, S. R. Smith, and A. G. Dulloo
Corticotropin-Releasing Hormone Directly Stimulates Thermogenesis in Skeletal Muscle Possibly through Substrate Cycling between de Novo Lipogenesis and Lipid Oxidation
Endocrinology, January 1, 2006; 147(1): 31 - 38.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Samuelsson, S.
Right arrow Articles by Isfort, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Samuelsson, S.
Right arrow Articles by Isfort, R. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


Guidelines | Subscriptions | About | exPRESS - Current - Archive | Business Information | Contact